EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT.-THALASSEMIA AND SEVERE SICKLE CELL DISEASE

被引：0

作者：

Locatelli, Franco ^{[1
]}

Frangoul, Haydar ^{[2
]}

Corbacioglu, Selim ^{[3
]}

de la Fuente, Josu ^{[4
]}

Wall, Donna ^{[5
]}

Cappellini, Maria Domenica ^{[6
]}

de Montalembert, Mariane ^{[7
]}

Kattamis, Antonis ^{[8
]}

Lobitz, Stephan ^{[9
]}

Rondelli, Damiano ^{[10
]}

Sheth, Sujit ^{[11
]}

Steinberg, Martin ^{[12
]}

Walters, Mark C. ^{[13
]}

Bobruff, Yael ^{[14
]}

Simard, Chris ^{[14
]}

Song, Yang ^{[14
]}

Zhang, Lanju ^{[14
]}

Sharma, Anjali ^{[15
]}

Imren, Suzan ^{[14
]}

Hobbs, Bill ^{[14
]}

Grupp, Stephan ^{[16
]}

机构：

[1] Osped Pediat Bambino Gesu, Rome, Italy

[2] Childrens Hosp, Sarah Cannon Ctr Blood Canc, Tri Star Centennial, Nashville, TN USA

[3] Univ Regensburg, Regensburg, Germany

[4] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England

[5] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada

[6] Univ Milan, Milan, Italy

[7] Univ Paris, Necker Enfants Malades Hosp, Assistance Publ Hop Paris, AP HP, Paris, France

[8] Univ Athens, Athens, Greece

[9] Gemeinschaftsklin Mittelrhein, Koblenz, Germany

[10] Univ Illinois, Chicago, IL USA

[11] Cornell Univ, Joan & Sanford Weill Med Coll, New York, NY USA

[12] Boston Univ, Sch Med, Boston, MA USA

[13] UCSF Benioff Childrens Hosp, Oakland, CA USA

[14] Vertex Pharmaceut Inc, Boston, MA USA

[15] CRISPR Therapeut, Cambridge, England

[16] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA USA

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O005

引用

页码：16 / 17

页数：2

共 50 条

[31] Safety of Autologous Hematopoietic Stem Cell Transplantation with Gene Addition Therapy for Transfusion-Dependent β-Thalassemia, Sickle Cell Disease, and Cerebral Adrenoleukodystrophy
Yannaki, Evangelia
Locatelli, Franco
Thrasher, Adrian J.
Tisdale, John F.
Orchard, Paul J.
Duncan, Christine N.
Kuehl, Joern-Sven
De Oliveira, Satiro
Sauer, Martin G.
Kulozik, Andreas E.
Hongeng, Suradej
Mapara, Markus Y.
Krishnamurti, Lakshmanan
Hermine, Olivier
Blanche, Stephane
Aubourg, Patrick
Smith, Nicholas
Shi, Weiliang
Colvin, Richard A.
McNeil, Elizabeth
Ribeil, Jean-Antoine
Cavazzana, Marina
Walters, Mark C.
Williams, David A.
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 75 - 76
[32] Neurocognitive function after allogeneic hematopoietic stem cell transplantation for sickle cell disease and transfusion dependent thalassemia
Kuhn-Wolff, E.
Troger, A.
Kleinschmidt, K.
Foell, J.
Hanafee-Alali, T.
Corbacioglu, S.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 447 - 448
[33] Global Longitudinal Myocardial Strain Correlates with Degree of Anemia in Sickle Cell Disease but Not Transfusion Dependent Thalassemia
Santi, Aura Daniella
Khang, Leepao
Spicer, Rosanna
Restrepo, Miguel
Sathi, Bindu K.
BLOOD, 2021, 138
[34] Clinical Outcomes of Molecular Matching in Transfusion-Dependent Patients with Sickle Cell Disease (SCD) and Thalassemia
de Macedo, Mayra Dorigan
dos Santos, Tamires Delfino
Perecin Menegati, Sheila Fatima
Pereira, Fabricio Biscaro
Gilli, Simone
Castilho, Lilian
TRANSFUSION, 2017, 57 : 137A - 138A
[35] BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY FOR THE TREATMENT OF TRANSFUSION-DEPENDENT β-THALASSEMIA (TDT): UPDATED LONG-TERM EFFICACY AND SAFETY RESULTS
Locatelli, F.
Yannaki, E.
Kwiatkowski, J. L.
Walters, M. C.
Porter, J. B.
Hongeng, S.
Kulozik, A. E.
Sauer, M. G.
Thrasher, A. J.
Thuret, I.
Lal, A.
Cavazzana, M.
Du, Lin
Colvin, R. A.
Rasko, J. E. J.
Algeri, M.
Thompson, A. A.
HAEMATOLOGICA, 2021, 106 (10) : 7 - 8
[36] EU Approval for first CRISPR/Cas9 Gene-Editing based Therapy Exagamgiogenic Autotemcel for the Treatment of Sickle Cell Disease and transfusion-dependent Beta-Thalassemia
不详
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 162 - 162
[37] BLOOD EXCHANGE TRANSFUSION SAFETY FOR PRIAPISM IN SICKLE CELL DISEASE: A SINGLE INSTITUTION REVIEW
Boucher, Maria
Obasaju, Patience
Park, Yara
Redding-Lallinger, Rupa
PEDIATRIC BLOOD & CANCER, 2016, 63 : S56 - S56
[38] MODEL-PROJECTED CLINICAL OUTCOMES OF EXAGAMGLOGENE AUTOTEMCEL (EXA-CEL) IN PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASOOCCLUSIVE CRISES IN CANADA
Udeze, C.
Gargano, M.
Kaindl, L.
Kane, S.
Zhou, A.
Jain, S.
Lopez, A.
VALUE IN HEALTH, 2024, 27 (12)
[39] Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Negre, Olivier
Bartholomae, Cynthia
Beuzard, Yves
Cavazzana, Marina
Christiansen, Lauryn
Courne, Celine
Deichmann, Annette
Denaro, Maria
de Dreuzy, Edouard
Finer, Mitchell
Fronza, Raffaele
Gillet-Legrand, Beatrix
Joubert, Christophe
Kutner, Robert
Leboulch, Philippe
Maouche, Leila
Paulard, Anais
Pierciey, Francis J., Jr.
Rothe, Michael
Ryu, Byoung
Schmidt, Manfred
von Kalle, Christof
Payen, Emmanuel
Veres, Gabor
CURRENT GENE THERAPY, 2015, 15 (01) : 64 - 81
[40] EU Approval for first CRISPR/Cas9 Gene-editing based Therapy Exagamglogenic autotemcel for the Treatment of Sickle Cell Disease and transfusion-dependent Beta-Thalassemia
Ruedesheim, Sabine M.
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2024, 51 (02) : 127 - 127

← 1 2 3 4 5 →